- Home
- MNSB vs AARD Comparison
MNSB vs AARD Comparison
Compare MNSB & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- AARD
- Stock Information
- Founded
- MNSB 2003
- AARD 2017
- Country
- MNSB United States
- AARD United States
- Employees
- MNSB N/A
- AARD N/A
- Industry
- MNSB Major Banks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- MNSB Finance
- AARD Health Care
- Exchange
- MNSB Nasdaq
- AARD Nasdaq
- Market Cap
- MNSB 170.1M
- AARD 186.3M
- IPO Year
- MNSB N/A
- AARD 2025
- Fundamental
- Price
- MNSB $19.70
- AARD $16.52
- Analyst Decision
- MNSB
- AARD Strong Buy
- Analyst Count
- MNSB 0
- AARD 7
- Target Price
- MNSB N/A
- AARD $31.43
- AVG Volume (30 Days)
- MNSB 37.0K
- AARD 183.9K
- Earning Date
- MNSB 10-27-2025
- AARD 11-14-2025
- Dividend Yield
- MNSB 2.05%
- AARD N/A
- EPS Growth
- MNSB N/A
- AARD N/A
- EPS
- MNSB N/A
- AARD N/A
- Revenue
- MNSB $64,604,000.00
- AARD N/A
- Revenue This Year
- MNSB $23.19
- AARD N/A
- Revenue Next Year
- MNSB $2.92
- AARD N/A
- P/E Ratio
- MNSB N/A
- AARD N/A
- Revenue Growth
- MNSB N/A
- AARD N/A
- 52 Week Low
- MNSB $15.00
- AARD $4.88
- 52 Week High
- MNSB $22.98
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- MNSB 26.62
- AARD 72.83
- Support Level
- MNSB $20.07
- AARD $10.75
- Resistance Level
- MNSB $20.52
- AARD $17.94
- Average True Range (ATR)
- MNSB 0.38
- AARD 1.19
- MACD
- MNSB -0.16
- AARD 0.46
- Stochastic Oscillator
- MNSB 13.06
- AARD 78.60
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.